Journal of the American Heart Association · 2026
Revisiting Glycemic Control Targets: Survival Outcomes by Glycated Hemoglobin Levels Among Patients With Diabetes Under Contemporary Antidiabetic Therapy.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Donna Shu-Han, Lo Hao-Yun, Lee Jen-Kuang
Аннотация
BACKGROUND: Optimal glycated hemoglobin (HbA1c) targets for type 2 diabetes remain controversial. Given the evolution of modern antidiabetic therapies, this study aims to reevaluate optimal glycemic targets among patients receiving contemporary glucose-lowering treatments.
METHODS: We conducted a retrospective cohort study using the National Taiwan University Hospital Integrated Medical Database, including 16 604 patients with type 2 diabetes who initiated dipeptidyl peptidase-4 inhibitors between 2009 and 2019, with follow-up through December 2021. Patients were categorized by long-term mean HbA1c quintiles. Outcomes included major adverse cardiovascular events (including ischemic stroke, myocardial infarction, cardiovascular death), renal outcomes (progression to dialysis, ≥50% estimated glomerular filtration rate decline, or doubling serum creatinine), hospitalization for heart failure, and safety outcomes. Associations were assessed using Cox proportional hazards models and restricted cubic spline analyses.
RESULTS: Compared with the third quintile as reference, the fourth (hazard ratio [HR], 1.22 [95% CI, 1.01-1.47]) and fifth quintiles (HR, 1.36 [95% CI, 1.12-1.64]) were associated with a significantly higher risk of major adverse cardiovascular events. Restricted cubic spline modeling identified significant J-shaped relationships for both major adverse cardiovascular events and renal outcomes, with the lowest risk observed around an HbA1c of 7%. In contrast, hospitalization for heart failure risk increased linearly with rising HbA1c levels. Notably, sex differences were identified: men showed a linear decrease in cardiovascular risk with lower HbA1c, whereas women exhibited a J-shaped relationship, indicating increased risks at both glycemic extremes.
CONCLUSION: Optimal glycemic targets among patients receiving contemporary therapies differ by outcome and sex. Individualized HbA1c management strategies are essential to balance cardiovascular and renal benefits against potential risks.
METHODS: We conducted a retrospective cohort study using the National Taiwan University Hospital Integrated Medical Database, including 16 604 patients with type 2 diabetes who initiated dipeptidyl peptidase-4 inhibitors between 2009 and 2019, with follow-up through December 2021. Patients were categorized by long-term mean HbA1c quintiles. Outcomes included major adverse cardiovascular events (including ischemic stroke, myocardial infarction, cardiovascular death), renal outcomes (progression to dialysis, ≥50% estimated glomerular filtration rate decline, or doubling serum creatinine), hospitalization for heart failure, and safety outcomes. Associations were assessed using Cox proportional hazards models and restricted cubic spline analyses.
RESULTS: Compared with the third quintile as reference, the fourth (hazard ratio [HR], 1.22 [95% CI, 1.01-1.47]) and fifth quintiles (HR, 1.36 [95% CI, 1.12-1.64]) were associated with a significantly higher risk of major adverse cardiovascular events. Restricted cubic spline modeling identified significant J-shaped relationships for both major adverse cardiovascular events and renal outcomes, with the lowest risk observed around an HbA1c of 7%. In contrast, hospitalization for heart failure risk increased linearly with rising HbA1c levels. Notably, sex differences were identified: men showed a linear decrease in cardiovascular risk with lower HbA1c, whereas women exhibited a J-shaped relationship, indicating increased risks at both glycemic extremes.
CONCLUSION: Optimal glycemic targets among patients receiving contemporary therapies differ by outcome and sex. Individualized HbA1c management strategies are essential to balance cardiovascular and renal benefits against potential risks.